UNASSIGNED: The purpose of this study was to determine what dose of @entity13613 , a serotonergic agonist, facilitates air-stepping and induces postural control and patterns of locomotion in newborn @entity35 . Subjects in both experiments were 1-day-old @entity35 pups. In Experiment 1, pups were restrained and tested for air-stepping in a 35-min test session. Immediately following a 5-min baseline, pups were treated with @entity13613 (1.0, 3.0, or 10.0mg/kg) or saline (vehicle control), administered intraperitoneally in a 50 L injection. Bilateral alternating stepping occurred most frequently following treatment with 10.0mg/kg @entity13613 , however the percentage of alternating steps, interlimb phase, and step period were very similar between the 3.0 and 10.0mg/kg doses. For interlimb phase, the forelimbs and hindlimbs maintained a near perfect anti-phase pattern of coordination, with step period averaging about 1s. In Experiment 2, pups were treated with 3.0 or 10.0mg/kg @entity13613 or saline, and then were placed on a surface (open field, unrestrained). Both doses of @entity13613 resulted in developmentally advanced postural control and locomotor patterns, including head elevation, postural stances, pivoting, crawling, and a few instances of quadrupedal walking. The 3.0mg/kg dose of @entity13613 was the most effective at evoking sustained locomotion. Between the 2 experiments, behavior exhibited by the @entity35 pup varied based on testing environment, emphasizing the role that environment and sensory cues exert over motor behavior. Overall, @entity13613 administered at a dose of 3.0mg/kg was highly effective at promoting alternating limb coordination and inducing locomotor activity in both testing environments.

Serotonergic activation of locomotor behavior and posture in one-day old XXXX .

@entity35 :: ('10116', 'Species') :: ['rat', 'rats'] @entity13613 :: ('MESH:D011814', 'Chemical') :: ['quipazine']
@entity35 :: (10116,Species) :: ['rats']
